Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, August 4, 2022
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Tuesday, July 26, 2022
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Wednesday, July 6, 2022
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
Tuesday, June 28, 2022
E.Design Insurance and Eisai Enter Into Business Alliance
Friday, June 24, 2022
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Wednesday, June 22, 2022
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
Monday, June 6, 2022
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Friday, June 3, 2022
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: